Welcome to our dedicated page for Galecto news (Ticker: GLTO), a resource for investors and traders seeking the latest updates and insights on Galecto stock.
Galecto Inc. (GLTO) is a clinical-stage biotechnology company pioneering small-molecule therapies for fibrosis and cancer. This page provides official updates on their innovative pipeline, including inhibitors targeting galectin-3 and LOXL2 proteins implicated in disease progression.
Investors and researchers will find timely announcements about clinical trials, regulatory milestones, and strategic collaborations. Key focus areas include updates on lead candidates like GB0139 for pulmonary fibrosis and GB1211 for oncology applications, alongside developments in combination therapies with immune checkpoint inhibitors.
All content is sourced directly from company releases to ensure accuracy. Bookmark this page to monitor progress across Galecto's therapeutic programs and stay informed about emerging data in precision medicine for fibrotic diseases and cancer.
Galecto (NASDAQ:GLTO) completed the acquisition of Damora Therapeutics and closed a concurrent Series C private placement raising approximately $284.9 million. The combined company says the financing provides runway into 2029 to advance Damora’s anti-mutCALR portfolio led by DMR-001, a monoclonal antibody with ~10-fold greater potency versus a reference molecule in preclinical Type 2 mutCALR models.
Key timelines: IND submission for DMR-001 expected mid-2026 and Phase 1 proof-of-concept data anticipated in 2027. Galecto also plans an IND for GB3226 in Q1 2026.
Galecto (NASDAQ: GLTO) reported third quarter 2025 operating and financial results on November 6, 2025. The company said it received constructive FDA pre-IND guidance for GB3226, a small-molecule dual ENL-YEATS/FLT3 inhibitor, and plans to submit an IND in Q1 2026 to start a Phase 1 AML trial evaluating safety, PK, preliminary efficacy and biomarkers with potential Phase 2 expansion.
Financials: $7.6M cash at Sept 30, 2025; R&D $1.4M (Q3 2025) vs $1.1M; G&A $1.7M vs $2.7M; net loss $3.1M or $(2.36)/share vs $3.9M prior-year quarter.
Galecto (NASDAQ: GLTO) will present preclinical data and clinical development plans for investigational candidate GB3226 at the 67th ASH Annual Meeting, Dec 6–9, 2025 in Orlando.
GB3226 is a first-in-class, orally bioavailable small molecule that dual-targets ENL-YEATS and FLT3, the latter mutated in ~30% of adult AML patients. Preclinical results reported include potent activity across diverse AML patient-derived samples, rapid tumor regression and prolonged survival in xenografts, favorable pharmacokinetics and tolerability in animals, and additive or synergistic effects with standard agents.
Galecto (NASDAQ: GLTO), a clinical-stage biotech company, reported Q2 2025 financial results and provided updates on its lead program. The company's primary focus is advancing GB3226, a dual ENL-YEATS and FLT3 inhibitor for AML treatment, with plans to submit an IND application to the FDA in Q1 2026.
Financial highlights include cash position of $10.2 million as of June 30, 2025, expected to fund operations into 2026. Q2 2025 saw a net loss of $3.4 million ($2.60 per share), improved from $5.3 million loss in Q2 2024. R&D expenses decreased to $1.5 million from $1.8 million, while G&A expenses reduced to $2.0 million from $2.8 million year-over-year.
Galecto (NASDAQ: GLTO) reported its Q1 2025 financial results and provided updates on its drug development programs. The company continues to advance GB3226, its dual ENL-YEATS and FLT3 inhibitor for acute myeloid leukemia (AML), with IND submission planned for Q1 2026. Preclinical data shows improved efficacy compared to existing treatments.
Financial highlights include:
- Cash position of $11.9 million as of March 31, 2025
- R&D expenses decreased to $0.7 million from $2.5 million year-over-year
- G&A expenses reduced to $1.9 million from $3.3 million year-over-year
- Net loss of $2.5 million ($1.92 per share) compared to $5.5 million ($5.05 per share) in Q1 2024
Galecto (NASDAQ: GLTO) has reported its full-year 2024 financial results and highlighted strategic developments. The company completed a strategic review focusing on oncology and liver diseases, acquiring global rights to GB3226, a dual ENL-YEATS and FLT3 inhibitor for AML treatment, with IND submission planned for Q1 2026.
Financial highlights include:
- Cash position of $14.2 million as of December 31, 2024
- R&D expenses decreased to $6.4 million from $23.8 million in 2023
- G&A expenses reduced to $10.5 million from $12.7 million in 2023
- Net loss of $21.4 million ($18.53 per share) compared to $38.3 million in 2023
The company continues its Phase 2 trial of GB1211 in combination with pembrolizumab for melanoma and head and neck cancer treatment. Current cash is expected to fund operations into 2026.
Galecto Inc (NASDAQ: GLTO), a clinical-stage biotechnology company developing treatments for cancer and severe liver diseases, has announced its participation in three major upcoming investor conferences.
The company will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, from 8:40-9:10 AM in a virtual format, featuring both a corporate presentation and one-on-one meetings. A live webcast will be available on Galecto's investor relations website, with replay access for 90 days.
Additionally, Galecto will attend the Leerink Partners Global Healthcare Conference on March 12 in Miami Beach, Florida, conducting one-on-one meetings, and the 37th Annual ROTH Conference on March 17-18 in Dana Point, CA, where they will deliver a corporate presentation and hold one-on-one meetings.
Galecto Inc (NASDAQ: GLTO) reported Q3 2024 financial results and strategic updates. The company completed a strategic review to focus on oncology and liver diseases, acquiring global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for acute myeloid leukemia (AML). Cash position stood at $19.7 million as of September 30, 2024. Q3 net loss was $3.9 million ($3.39 per share), improved from $8.1 million loss year-over-year. R&D expenses decreased to $1.1 million from $2.6 million, while G&A expenses reduced to $2.7 million from $3.3 million in Q3 2023.
Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on developing novel treatments for cancer and fibrosis, has appointed Dr. Amy Wechsler to its Board of Directors. Dr. Wechsler, board-certified in both dermatology and psychiatry, brings a unique combination of expertise and leadership experience in healthcare. She has been a practicing dermatologist since 2005 and has served on the Board of Directors for Bausch Health since 2016. Dr. Wechsler is also an adjunct clinical professor of psychiatry at Weill Cornell Medical College.
Dr. Carl Goldfischer, Chair of the Board of Galecto, expressed enthusiasm for Dr. Wechsler's appointment, highlighting her experience in guiding companies through critical growth stages. Dr. Wechsler holds a B.S. in psychology from Duke University, an M.D. from Cornell University Medical College, and recently earned an M.B.A. from Columbia Business School in 2024.
Galecto, Inc. (NASDAQ: GLTO) has announced a strategic shift to focus on cancer and liver disease, leveraging its clinical-stage asset GB1211. The company has also acquired global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for acute myeloid leukemia (AML), from Bridge Medicines.
Key points:
- GB1211 has shown positive results in non-small cell lung cancer and decompensated cirrhosis studies
- BRM-1420 has potential for enhanced clinical effectiveness compared to FLT3 inhibitors alone
- Galecto issued 62,594 shares of common stock and 160.562 shares of new Series A preferred stock to Bridge Medicines as consideration
- Matthew Kronmiller, Bridge Medicine's CEO, will join Galecto as EVP of Strategy and Chief Business Officer
The strategic review aims to build value and develop breakthrough treatments for oncology and liver conditions.
FAQ
What is the current stock price of Galecto (GLTO)?
What is the market cap of Galecto (GLTO)?
